Mitsui Petrochemical Industries, Ltd.

Mitsui Toatsu Chemicals, Incorporated

Mitsui Pharmaceuticals, Inc.

Mitsui Chemicals, Inc.

Schering Aktiengesellschaft

Kazutoshi Horikomi

Akira Mizuchi

Akira Awaya

Ikuo Tomino

Kazuya Sakai

Tadayuki Sasaki

Noriaki Kihara

Akira Matsubara

Takumi Kitahara

Norio Ohto

Hideki Tanada

Keiichi Yokoyama

Takuo Nakano

Seitaro Kajiya

Hideshi Shimizu

Takahisa Oguchi

Hajime Iizuka

Hisashi Kobayashi

Masaharu Ishiguro

Mitsuyuki Takesue

Takaichi Miwa

Takeshi Kamioka

Ken Ikeda

Masaru Honjo

Joji Kamiya

Hiroyasu Ohno

Shintaro Araki

Masaaki Ishii

Koji Kato

Shigeru Isayama

Hiroshi Nagase

Naruyoshi Mita

Yoji Aoki

Kanji Yoshihara

Noriaki Asada

Takuma Ohtsu

Yuichiro Kokubun

Ken E Tan

Shoji Kawashima

Kozi Kato

Shinji Takahashi

Miwa Ikeda

Administration of an administrative amount of an authentic human growth hormone having a molecular weight of 20,000 daltons to human adults can improve body composition, stimulate lipolysis, increase serum insulin-like growth factor I or be used in replacement therapy for human growth hormone-deficient patients.

Therapeutic use of 20-kilodalton human growth hormone

Since a compound represented by general formula (1), its pharmaceutically acceptable salt and a hydrate of the pharmaceutically acceptable salt have high antipsychotic activity, they may be used as an active ingredient for preparation of an antipsychotic. ##STR1## Also provided are an optical resolution method of the above compound and an intermediate for preparation of the compound.

Pyrrolidinone derivatives

Aminoketone derivative compounds containing a heterocyclic ring bonded to an aminoketone moiety and useful as effective ingredients of centrally acting muscle relaxants and pollakiurea curing agents. (+)3-phenyl-5-[2-(1-pyrrolidinylmethyl)butyryl] isoxazole, which has a more remarkable central muscle relaxant action as compared with its racemic modification, can be effectively separated from the racemic modification using optically active 10-camphorsulfonic acid as the agent for the optical resolution.

Aminoketone derivatives and use thereof

Antipsychotics and ischemic cerebral disease therapeutics comprising as an effective ingredient a compound represented by the following formula (1) or (2): ##STR1## or a salt thereof. These drugs do not induce extrapyramidal side effects.

Aminoketone derivative compounds containing a heterocyclic ring bonded to an aminoketone moiety and useful as effective ingredients of centrally acting muscle relaxants and pollakiurea curing agents. (+)3-phenyl-5-[2-(1-pyrrolidinylmethyl)butyryl]isoxazole, which has a more remarkable central muscle relaxant action as compared with its racemic modification, can be effectively separated from the racemic modification using optically active 10-camphorsulfonic acid as the agent for the optical resolution.

Aminoketone derivative and use thereof

Pyrimidine compound and pharmaceutically acceptable salts thereof

Aminoketone derivatives of 1,2-oxazole and use thereof

This invention provides novel pyrimidines or their pharmaceutically acceptable salts thereof and process for preparation thereof. The novel compounds are useful for neurological diseases of the peripheral and central nervous systems of animals.

Pyrimidines and pharmaceutically acceptable salts thereof useful in

2,6-di-, 2,4,6-, 2,5,6-tri- or 2,4,5,6-tetra-substituted pyrimidines, and 2,6-di-substituted pyridines. These compounds are useful for treatment of neurological deseases.

Pyrimidines and their pharmaceutical acceptable salts, and their use as

Amine represented by the following formula (1), or their acid addition salts or their quaternary ammonium salts. ##STR1## The amines of formula (1) or their pharmaceutically acceptable acid addition salts or quaternary ammonium salts are useful for the treatment and prevention of heart diseases of animals, particularly arrhythima, myocardial infarction, angina pectoris and heart failure and psychoneurological diseases.

Coumaran group containing amine compounds and their acid addition salts

2,6-di-, 2,4,6-, 2,5,6-tri- or 2,4,5,6-tetra-substituted pyrimidines, and 2,6-di-substituted pyridines. These compounds are useful for treatment of neurological diseases.

2,6-di,2,4,6-, 2,5,6-tri and 2,4,5,6-tetra-substituted pyrimidines,

Described herein are imidazole derivatives having a specific structure and satisfactory as antiepileptics from the standpoint of the strength of action, prolonged action and side effects as well as their preparation processes.

Imidazole derivatives and antiepileptics comprising said imidazole

Therapeutic agent for neurological diseases

Growing community of inventors

Mobara, Japan

Kazutoshi Horikomi